secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000320017-25-000059
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Q2 net loss $4.7M, cash $22M; certepetide trials advancing with multiple data milestones ahead
--------------------------------------------------------------------------------

- Net loss of $4.7M vs $5.0M in Q2 2024; revenue of $70K from Catalent license fee.
- Cash, equivalents and securities total $22.0M; runway into Q4 2026 funds all active trials to next data milestone.
- ASCEND Phase 2b Cohort B showed positive PFS and ORR signal; final data expected late 2025.
- BOLSTER Phase 2a first-line CCA enrollment complete; topline data due Q4 2025.
- USPTO issued new composition-of-matter patent for certepetide (U.S. 12,351,653) extending protection to March 2040.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000059/0000320017-25-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000059/clbs-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000320017-25-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer